Clinical trials: LDL Cholesterol
Hyperlipemia
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study of SYH2053 when administered subcutaneously to subjects with normal and elevated LDL-C.
- Trial name
- NCT06229548
- Testing
- SYH2053
- Where
- China
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Hypercholesterolemia, Cardiovascular Risk Factor
The Effect of Psyllium Fibre on LDL-C, Non-HDL-C, and Apolioprotein-B: A Systematic Review and Meta-analysis
Serum cholesterol is a major modifiable risk factor for cardiovascular disease, which despite considerable reduction in prevalence, remains the leading cause of premature mortality worldwide.
- Trial name
- NCT03346733
- Testing
- Psyllium Fibre
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Dyslipidemias, Cardiovascular Risk Factor
Meta-analyses of Soy Protein and Its Food Sources for Cholesterol Reduction
Although soy protein has approved health claims in Canada and the US, and is recognized by major cardiovascular clinical practice guidelines for the reduction of cholesterol and risk of coronary heart disease (CHD), these claims…
- Conditions
- Dyslipidemias, Cardiovascular Risk Factor, Dysglycemia
- Trial name
- NCT04861545
- Testing
- Soy
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- John Sievenpiper
Lipids, Lipid Metabolism
RISSCI-1 Blood Cholesterol Response Study
Raised blood cholesterol (also referred to as blood LDL-cholesterol) is a major risk factor for developing heart disease. Dietary saturated fat is recognised as the main dietary component responsible for raising blood…
- Conditions
- Lipids, Lipid Metabolism, Healthy
- Trial name
- RISSCI-1 (NCT03270527)
- Testing
- High SFA diet (Diet 1), Low SFA diet (Diet 2)
- Where
- 2 sites in United Kingdom
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Cardiovascular Diseases
Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America
Post-Marketing Observational study of Niaspan® tablet in accordance with each country regulations. This study will be conducted in a prospective, single-arm, multi-center format.
- Trial name
- NCT01200160
- Testing
- Niacin
- Where
- 22 sites in Colombia, Mexico and 1 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Abbott
Change in Fasting Plasma LDL-cholesterol Concentration After the Consumption of Quinoa
Effects of Quinoa Consumption on Markers of Cardiovascular Risk and Gastrointestinal Health
Quinoa is possible alternative to wheat, corn and rice due to its high nutritional value and possible properties against cardiovascular diseases and for improving gut health.
- Trial name
- NCT03036618
- Testing
- Quinoa, Wheat
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Newcastle University
Above Optimal Plasma LDL Concentrations
Flax Muffins and Cholesterol Lowering
This Clinical Trial is being conducted to study the LDL (bad) cholesterol lowering abilities of flax. The purpose of this study is to find the lowest dose of flax that can lower LDL-cholesterol.
- Trial name
- NCT01821131
- Testing
- muffin
- Where
- 2 sites in Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- St. Boniface Hospital
Lipid Metabolism, Inborn Errors, Hyperlipidemias
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis.
- Conditions
- Lipid Metabolism, Inborn Errors, Hyperlipidemias, Metabolic Diseases, Hypolipoproteinemia
- Trial name
- NCT00362180
- Testing
- mipomersen
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Kastle Therapeutics, LLC
Dyslipidemia, Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients
This study will assess the safety, tolerability, and effect of TAP311 on blood lipids in healthy subjects and in patients who have dyslipidemia.
- Trial name
- NCT01487460
- Testing
- TAP311
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
LDL Cholesterol
Effect of Viscous Soluble Fibers on Serum Cholesterol Levels
Research over the past several decades have linked the intake of dietary fiber with lower blood cholesterol levels. The distinction between soluble and insoluble fiber fractions emerged shortly after and there is now a general…
- Trial name
- CHOL-META (NCT02068248)
- Testing
- Soluble Fibre
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Delivery of Health Care
Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia
The purpose of this study is to validate the effectiveness of food supplement Limicol on reducing LDL-cholesterol in moderate hypercholesterolemic volunteers.
- Trial name
- NCT01139398
- Testing
- Limicol (plant extract)
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Lescuyer Laboratory
Hypercholesterolemia
Effect of the Molecular Weight of Oat β-glucan on Its Ability to Lower Serum Cholesterol
The purposes of this study were: 1. To determine if a breakfast cereal containing 3g of high molecular weight oat beta-glucan fiber would lower low-density lipoprotein (LDL) - cholesterol (the "bad" cholesterol) compared to a…
- Trial name
- Bluebird (NCT00981981)
- Testing
- Wheat bran, 3g high MW, 4g medium MW
- Where
- 5 sites in Australia, Canada and 1 more
- Volunteers
- 367 people, healthy volunteers welcome
- Sponsor
- Glycemic Index Laboratories, Inc
Elevated Low-Density Lipoprotein Cholesterol
Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol
This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single and multiple dose escalation study with SC doses of SNK-396 in participants with elevated LDL-C.
- Trial name
- NCT05896969
- Testing
- SNK-396 - SAD cohort, SNK-396 - MAD Cohort
- Where
- 3 sites in Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Dyslipidemia
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
- Trial name
- NCT06742853
- Testing
- AZD0780, Ezetimibe, Rosuvastatin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1, Hyperlipidemias
Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus
This is a prospective, randomized, double blind, parallel, placebo controlled clinical trial evaluating the efficacy of colesevelam HCl in reducing LDL in subjects with type 1 diabetes mellitus over a 12 week treatment period.
- Trial name
- NCT00938405
- Testing
- Colesevelam HCl
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hypercholesterolemia, Dyslipidemia
Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin
The primary objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of a single dose of PF-04950615 (RN316) in volunteers on stable doses of atorvastatin.
- Trial name
- NCT01163851
- Testing
- 4 mg/kg, 0.5 mg/kg
- Where
- 5 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Borderline High LDL-cholesterol
Effects of Ubiquinol and Ubiquinone on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol
This randomized, double-blind, placebo-controlled clinical trial will evaluate the effects of Ubiquinol and Ubiquinone on vascular endothelial function in generally healthy adults with borderline high LDL-cholesterol.
- Trial name
- NCT07881601
- Testing
- Ubiquinol, Ubiquinone
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- SF Research Institute, Inc.
Impaired Glucose Tolerance
Low Density Lipoprotein (LDL) Cholesterol Metabolism in Impaired Glucose Tolerance
Impaired glucose tolerance is associated with an increased risk of developing cardiovascular disease and atherosclerosis for reasons not yet totally understood.
- Trial name
- NCT01020578
- Testing
- Plasma kinetic study
- Where
- Brazil
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Healthy Volunteers
Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers
The goal of this study is to assess the effects of a dietary supplement on fasting lipoprotein lipids and a marker of inflammation in men and women with levels of low-density lipoprotein cholesterol above desirable levels.
- Trial name
- NCT03118583
- Testing
- 300 mg/day of dietary supplement containing carrageenan
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Midwest Center for Metabolic and Cardiovascular Research
Hypercholesterolemia, Coronary Heart Disease
Addition of Phytosterols to a Low Phytosterol Diet
Studies have shown that phytosterols will lower LDL cholesterol. Typical diets can contain between 250 to 500 mg of naturally-occurring phytosterols.
- Trial name
- phyteaux-I (NCT00860054)
- Testing
- Different amount of phytosterols are added into diets
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine